Ocular Therapeutix (NASDAQ:OCUL) & Statera Biopharma (NASDAQ:STAB) Critical Comparison

Statera Biopharma (NASDAQ:STAB) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares Statera Biopharma and Ocular Therapeutix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Statera Biopharma	N/A	N/A	N/A
Ocular Therapeutix	-283.74%	-45.18%	-30.87%

Analyst Recommendations

This is a breakdown of recent ratings for Statera Biopharma and Ocular Therapeutix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Statera Biopharma	0	0	0	0	0.00
Ocular Therapeutix	0	1	6	0	2.86

Ocular Therapeutix has a consensus price target of $16.71, indicating a potential upside of 88.01%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Statera Biopharma.

Insider & Institutional Ownership

59.2% of Ocular Therapeutix shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by company insiders. Comparatively, 3.5% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Statera Biopharma has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.

Earnings & Valuation

This table compares Statera Biopharma and Ocular Therapeutix”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Statera Biopharma	$1.49 million	0.00	-$101.85 million	N/A	N/A
Ocular Therapeutix	$61.44 million	22.75	-$80.74 million	($1.32)	-6.73

Ocular Therapeutix has higher revenue and earnings than Statera Biopharma.

Summary

Ocular Therapeutix beats Statera Biopharma on 7 of the 11 factors compared between the two stocks.

About Statera Biopharma

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.

About Ocular Therapeutix

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.